ATE446951T1 - Verwendung einer verbingung gemäss formel i zur herstellung einer pharmazeutischen zubereitung - Google Patents

Verwendung einer verbingung gemäss formel i zur herstellung einer pharmazeutischen zubereitung

Info

Publication number
ATE446951T1
ATE446951T1 AT03090177T AT03090177T ATE446951T1 AT E446951 T1 ATE446951 T1 AT E446951T1 AT 03090177 T AT03090177 T AT 03090177T AT 03090177 T AT03090177 T AT 03090177T AT E446951 T1 ATE446951 T1 AT E446951T1
Authority
AT
Austria
Prior art keywords
independently selected
optionally substituted
valence bond
optionally
hydrogen
Prior art date
Application number
AT03090177T
Other languages
English (en)
Inventor
Ricardo Biondi
Matthias Engel
Original Assignee
Biondi Ricardo Miguel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biondi Ricardo Miguel filed Critical Biondi Ricardo Miguel
Application granted granted Critical
Publication of ATE446951T1 publication Critical patent/ATE446951T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/12—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
    • C07C233/15—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/87—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03090177T 2003-06-10 2003-06-10 Verwendung einer verbingung gemäss formel i zur herstellung einer pharmazeutischen zubereitung ATE446951T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03090177A EP1486488B1 (de) 2003-06-10 2003-06-10 Verwendung einer Verbingung gemäss Formel I zur Herstellung einer pharmazeutischen Zubereitung

Publications (1)

Publication Number Publication Date
ATE446951T1 true ATE446951T1 (de) 2009-11-15

Family

ID=33185917

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03090177T ATE446951T1 (de) 2003-06-10 2003-06-10 Verwendung einer verbingung gemäss formel i zur herstellung einer pharmazeutischen zubereitung

Country Status (5)

Country Link
US (1) US20070032474A1 (de)
EP (1) EP1486488B1 (de)
AT (1) ATE446951T1 (de)
DE (1) DE60329831D1 (de)
WO (1) WO2004111008A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105563B2 (en) 2003-10-24 2006-09-12 Schering Aktiengesellschaft Indolinone derivatives and their use in treating disease-states such as cancer
WO2007106537A2 (en) * 2006-03-13 2007-09-20 Activx Biosciences, Inc. Aminoquinolones as gsk-3 inhibitors
US20070286864A1 (en) * 2006-06-09 2007-12-13 Buck Elizabeth A Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors
WO2008019890A2 (en) * 2006-08-18 2008-02-21 Biondi Ricardo M Method of modulation of protein phosphorylation-dependent conformational transitions with low molecular weight compounds
CN101855228B (zh) 2007-09-11 2012-10-24 杏林制药株式会社 作为gsk-3抑制剂的氰基氨基喹诺酮和四唑并氨基喹诺酮
US8476261B2 (en) 2007-09-12 2013-07-02 Kyorin Pharmaceutical Co., Ltd. Spirocyclic aminoquinolones as GSK-3 inhibitors
WO2009151618A2 (en) 2008-06-10 2009-12-17 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Methods and compositions for treating alzheimer's disease
EP2177510A1 (de) 2008-10-17 2010-04-21 Universität des Saarlandes Allosterische Proteinkinasemodulatoren
WO2010104306A2 (ko) * 2009-03-07 2010-09-16 주식회사 메디젠텍 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 ｇｓｋ３ 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
KR101748891B1 (ko) 2009-03-11 2017-06-19 교린 세이야꾸 가부시키 가이샤 Ｇｓｋ-3 억제제로서의 7-시클로알킬아미노퀴놀론
WO2013024028A1 (en) * 2011-08-12 2013-02-21 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compounds and compositions for treating proteinopathies
WO2015075051A1 (en) 2013-11-19 2015-05-28 Universitaet Des Saarlandes Allosteric inhibitors of atypical protein kinases c
US20160331746A1 (en) 2015-05-12 2016-11-17 University Of South Florida Sortilin-Binding Small Molecules for Increasing Glucose Uptake
CA2992945A1 (en) 2015-07-17 2017-01-26 Memorial Sloan-Kettering Cancer Center Combination therapy using pdk1 and pi3k inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1165064B1 (de) * 1999-04-05 2004-02-25 City of Hope Neue hemmern von fortgeschrittenen glykosilierung-endprodukten
US6037357A (en) * 1999-04-21 2000-03-14 Unitech Pharmaceuticals, Inc. N-benzoyl-α-alkylated azatyrosines as anticancer agents
TWI262185B (en) * 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
IL136458A0 (en) * 2000-05-30 2001-06-14 Peptor Ltd Protein kinase inhibitors
CZ20031194A3 (cs) * 2000-09-29 2003-08-13 Glaxo Group Limited Deriváty močoviny
AU2002309083A1 (en) * 2001-03-30 2002-10-15 Biocrine Ab Method for identifying drugs for the treatment of type ii diabetes
US20040005687A1 (en) * 2001-08-14 2004-01-08 The Institute Of Cancer Research Kinase crystal structures

Also Published As

Publication number Publication date
US20070032474A1 (en) 2007-02-08
EP1486488B1 (de) 2009-10-28
WO2004111008A2 (en) 2004-12-23
WO2004111008A3 (en) 2005-03-17
DE60329831D1 (de) 2009-12-10
EP1486488A1 (de) 2004-12-15

Similar Documents

Publication Publication Date Title
DE60329831D1 (de) Verwendung einer Verbingung gemäss Formel I zur Herstellung einer pharmazeutischen Zubereitung
EP1795536A4 (de) Phosphoramiditverbindung und verfahren zur herstellung von oligo-rna
EA200300428A1 (ru) Антагонисты метаботропных рецепторов глутамата
ATE313535T1 (de) Pyrazinyl-piperazin-verbindungen, ihre anwendung und herstellung
CY1109222T1 (el) Παραγωγο συγχωνευμενης κινολινης και χρηση του
DE68906183D1 (de) 2'-desoxy-5-fluoruridinderivate.
ATE338754T1 (de) Heterocyclische verbindungen, ihre herstellung und verwendung
ATE427932T1 (de) 11beta-hsd1-inhibitoren
NL300194I1 (nl) Nieuwe tricyclische verbindingen.
EA200500018A1 (ru) Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения
MXPA04009784A (es) Tiazolidin-4-carbonitrilos y analogos y su uso como inhibidores de dipeptidil-peptidas.
EA199800794A1 (ru) Новые производные арилглициламида, способ их получения и фармацевтическая композиция, содержащая эти соединения
WO2005040345A3 (en) 4-azole substituted imidazole compositions useful as inhibitors or c-met receptor tyrosine kinase
EP1775289A4 (de) Neue imidazolidinderivate
DE69937045D1 (de) Cyclische amidderivate
ATE290527T1 (de) Tetrahydrobenzindol-derivate
ATE211137T1 (de) Substituierte benzylthienylpiperazine, ihre anwendung als arzneimittel und verfahren für ihre herstellung
EA200401077A1 (ru) 2-оксазоламины и их применение в качестве антагонистов рецептора 5-ht2b
ATE195313T1 (de) 3-substituierte 1-arylindolverbindungen
EA200500683A1 (ru) Новые соединения пирролидина и тиазолидина, способ их получения и фармацевтические композиции, которые их содержат
ATE386735T1 (de) Substituierte benzoylureidopyridyl-piperidin- und pyrrolidin-carbons urederivate, verfahren zu deren herstellung und deren v erwendung
EA200600551A1 (ru) Соединения пиперазина, способ их получения и фармацевтические композиции, которые их содержат
EP0825180A4 (de) 1-omega-(3,4-dihydro-2-naphtalenyl)alkyl derivate zyklischer amine, verfahren zu ihrer herstellung und medizinische zusammensetzung die diese enthält
NO20053997L (no) Oligosaccharidderivat
ATE234315T1 (de) Medikamente gegen trhombocytopenie

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties